Good Manufacturing Practice– tag –
-
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat... -
Winship Cancer Institute Launches Cellular Therapy Initiative, Expanding GMP Manufacturing Capacity for Next-Generation Cancer Treatments
Winship Cancer Institute USA Overview The Winship Cancer Institute has launched a Cellular Therapy Initiative to accelerate the development of next-generation cancer treatments. This initiative significantly expands GMP manufacturing cap... -
Samsung Biologics to Acquire PolyPeptide Group for $1.8B, Expanding CDMO Capabilities into Peptide Therapeutics with $2.2B Capital Raise
Endpoints News South Korea Overview Samsung Biologics announced a capital raise of nearly $2.2 billion to fund its long-term growth strategy, including the acquisition of PolyPeptide Group for $1.8 billion. This acquisition will signific... -
Liv Hospital Charts Course for Scalable CAR-T Production with Comprehensive GMP and Bioreactor Guide
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive guide detailing the critical, GMP-compliant manufacturing process for CAR-T cell therapies, from T-cell collection and genetic modification to controlled expansion in... -
Texas Children’s Hospital’s GMP Facility Manufactures Over 10,000 Cell Therapy Products in 20 Years, Driving CGT Innovation
Texas Children's Hospital USA Overview Texas Children's Hospital's Center for Cell and Gene Therapy (CAGT) has manufactured over 10,000 cell therapy products and more than 70 clinical-grade viral vectors over two decades, utilizing its i... -
Viral Vector CDMO Capacity Exceeds Clinical Demand: Catalent and Lonza Lead AAV Manufacturing Expansion
IntuitionLabs USA Overview An August 2026 analyst report reveals that viral vector manufacturing capacity, especially for AAV, has outpaced current clinical demand, offering gene therapy sponsors more options and competitive lead times. ... -
Sartorius Accelerates Cell & Gene Therapy Commercialization with Comprehensive End-to-End Solutions
Sartorius Germany Overview Sartorius emphasizes its mission to accelerate the commercialization of cell and gene therapies (CGT) by providing end-to-end solutions that deliver reproducible performance and scalability. Its portfolio suppo... -
Creative Life Science Unveils PIC/S GMP-Compliant Cell Therapy Platform at BIO Asia-Taiwan 2026, Bolstered by New Taiwan Regenerative Medicine Laws
PR Newswire Taiwan Overview According to PR Newswire, Creative Life Science is showcasing its PIC/S GMP-compliant cell therapy materials and manufacturing platform at BIO Asia-Taiwan 2026. The company's Zhubei biomanufacturing facility s... -
Histocell Accelerates Advanced Cell Therapy Production with New 800m² GMP Facility, Targeting 1,200 Annual Batches
REPROCELL Spain Overview Histocell has inaugurated an 800m² Advanced Therapies GMP facility, dramatically increasing its cell manufacturing capacity to an estimated 1,200 batches annually for both autologous and allogeneic treatments. Th... -
University of Illinois Opens “TORM,” its First cGMP Facility Integrating Cancer Treatment and Regenerative Medicine
University of Illinois College of Medicine USA Overview The University of Illinois has inaugurated the "Translational Oncology and Regenerative Medicine Laboratory (TORM)," its first facility combining cancer treatment and regenerative m...
12